| Print
Viatris (VTRS)
Common SharesOpen
$16.01
Previous close
$16.12
Trade high
$16.37
Volume
6,494,519
Year high
$18.39
Year low
$9.425
Dividend yield
2.98%
Market capitalisation
$18.75 bn
P/E ratio
236.20
ISIN
US92556V1061
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Share price
Dividends
| Previous | Latest | |
|---|---|---|
| Record date | 22/05/2026 | 21/08/2026 |
| Ex-dividend date | 22/05/2026 | 21/08/2026 |
| Payment date | 17/06/2026 | 16/09/2026 |
| Amount | $0.12 | $0.12 |
Company profile
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.